Please enable JavaScript to continue using this application.

Compare $ICCC vs $PTHS | Chartloom

Compare

$ICCC vs $PTHS

ImmuCell Corp · Pelthos Therapeutics Inc

ICCC

ImmuCell Corp

PTHS

Pelthos Therapeutics Inc

Compare $ICCC vs $PTHS

Comparing ImmuCell Corp and Pelthos Therapeutics Inc

ICCCImmuCell Corp

PTHSPelthos Therapeutics Inc

ICCCImmuCell Corp

Market cap

$89M

P/E (TTM)

114.37x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

8.5%

YTD performance

65.5%

52W performance

48.7%

FCF yield

4.8%

PTHSPelthos Therapeutics Inc

Market cap

$71M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.83x

Rev growth (TTM)

—

YTD performance

-30.4%

52W performance

-27.4%

FCF yield

-70.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ICCC

PTHS

Detailed metrics comparison

ICCC

ImmuCell Corp

PTHS

Pelthos Therapeutics Inc

Market Cap

ICCC$89M

PTHS$71M

Enterprise Value

ICCC$88M

PTHS$71M

Price

ICCC$9.80

PTHS$20.50

P/E Ratio

ICCC114.37x

PTHSN/A

P/S Ratio

ICCC2.89x

PTHS1.65x

EV/Sales

ICCC2.87x

PTHS1.65x

EV/EBITDA

ICCC14.10x

PTHS0.00x

P/B Ratio

ICCC2.82x

PTHS2.03x

P/FCF Ratio

ICCC21.04x

PTHSN/A

EV/FCF

ICCC20.91x

PTHS-1.41x

PEG Ratio

ICCCN/A

PTHSN/A

Forward P/E (NTM)

ICCCN/A

PTHSN/A

Forward P/S (NTM)

ICCCN/A

PTHS0.83x

Revenue (TTM)

ICCC$31M

PTHS$43M

Revenue Growth (YoY)

ICCC8.5%

PTHSN/A

Forward Rev Growth

ICCC0.0%

PTHS76.2%

Gross Margin (TTM)

ICCC40.3%

PTHS78.6%

Operating Margin (TTM)

ICCC3.9%

PTHS0.0%

EBITDA Margin (TTM)

ICCC20.4%

PTHS-121.6%

Net Margin (TTM)

ICCC2.6%

PTHS-165.2%

FCF Margin (TTM)

ICCC13.7%

PTHS-116.6%

Net Income (TTM)

ICCC$787K

PTHS$-72M

FCF (TTM)

ICCC$4M

PTHS$-50M

EPS (TTM)

ICCC$0.09

PTHS-$20.22

ROE (TTM)

ICCC2.7%

PTHS-7804.0%

ROA (TTM)

ICCC1.8%

PTHS-6701.0%

ROIC (TTM)

ICCC2.1%

PTHS-5896.0%

Cash

ICCC$9M

PTHS$0

Debt

ICCC$8M

PTHS$0

Net Cash/Debt

ICCC$557K

PTHS$0

Current Ratio (TTM)

ICCC4.75x

PTHS2.05x

Quick Ratio (TTM)

ICCC2.65x

PTHS1.10x

Debt/Equity (TTM)

ICCC0.26x

PTHS0.81x

Debt/Assets (TTM)

ICCC0.0%

PTHS0.0%

Interest Coverage (TTM)

ICCCN/A

PTHSN/A

Net Debt/EBITDA (TTM)

ICCC0.00x

PTHS0.00x

Beta

ICCC0.60

PTHS3.13

52W Performance

ICCC48.7%

PTHS-27.4%

YTD Performance

ICCC65.5%

PTHS-30.4%

% from 52W High

ICCC-19.0%

PTHS-45.3%

% from 52W Low

ICCC116.8%

PTHS12.7%

Asset Turnover (TTM)

ICCC0.69x

PTHS0.00x

FCF Yield (TTM)

ICCC4.8%

PTHS-70.8%

Earnings Yield (TTM)

ICCC0.9%

PTHS-100.3%

Dividend Yield (TTM)

ICCCN/A

PTHSN/A

Rule of 40

ICCC22.2

PTHS-116.6

EV/GP/RG

ICCCN/A

PTHS0.02

Ticker research

View ICCC research View PTHS research

Metric	ICCC ImmuCell Corp	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$89M	$71M
Enterprise Value	$88M	$71M
Price	$9.80	$20.50
P/E Ratio	114.37x	N/A
P/S Ratio	2.89x	1.65x
EV/Sales	2.87x	1.65x
EV/EBITDA	14.10x	0.00x
P/B Ratio	2.82x	2.03x
P/FCF Ratio	21.04x	N/A
EV/FCF	20.91x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.83x
Revenue & Growth
Revenue (TTM)	$31M	$43M
Revenue Growth (YoY)	8.5%	N/A
Forward Rev Growth	0.0%	76.2%
Profitability
Gross Margin (TTM)	40.3%	78.6%
Operating Margin (TTM)	3.9%	0.0%
EBITDA Margin (TTM)	20.4%	-121.6%
Net Margin (TTM)	2.6%	-165.2%
FCF Margin (TTM)	13.7%	-116.6%
Net Income (TTM)	$787K	$-72M
FCF (TTM)	$4M	$-50M
EPS (TTM)	$0.09	-$20.22
ROE (TTM)	2.7%	-7804.0%
ROA (TTM)	1.8%	-6701.0%
ROIC (TTM)	2.1%	-5896.0%
Financial Health
Cash	$9M	$0
Debt	$8M	$0
Net Cash/Debt	$557K	$0
Current Ratio (TTM)	4.75x	2.05x
Quick Ratio (TTM)	2.65x	1.10x
Debt/Equity (TTM)	0.26x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.60	3.13
52W Performance	48.7%	-27.4%
YTD Performance	65.5%	-30.4%
% from 52W High	-19.0%	-45.3%
% from 52W Low	116.8%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.69x	0.00x
FCF Yield (TTM)	4.8%	-70.8%
Earnings Yield (TTM)	0.9%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	22.2	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View ICCC research	View PTHS research

Valuation

P/E Ratio

ICCC

114.37x

P/S Ratio

PTHS

1.65x

ICCC

2.89x

EV/FCF

PTHS

-1.41x

ICCC

20.91x

Growth & revenue

Revenue Growth TTM

ICCC

8.5%

Forward Revenue Growth

PTHS

76.2%

ICCC

0.0%

Profitability & performance

Gross Margin

PTHS

78.6%

ICCC

40.3%

ROE

ICCC

2.7%

PTHS

-7804.0%

FCF Yield %

ICCC

4.8%

PTHS

-70.8%

52-Week Performance

ICCC

48.7%

PTHS

-27.4%

Detailed metrics comparison

ICCC

ImmuCell Corp

PTHS

Pelthos Therapeutics Inc

Market Cap

ICCC$89M

PTHS$71M

Enterprise Value

ICCC$88M

PTHS$71M

Price

ICCC$9.80

PTHS$20.50

P/E Ratio

ICCC114.37x

PTHSN/A

P/S Ratio

ICCC2.89x

PTHS1.65x

EV/Sales

ICCC2.87x

PTHS1.65x

EV/EBITDA

ICCC14.10x

PTHS0.00x

P/B Ratio

ICCC2.82x

PTHS2.03x

P/FCF Ratio

ICCC21.04x

PTHSN/A

EV/FCF

ICCC20.91x

PTHS-1.41x

PEG Ratio

ICCCN/A

PTHSN/A

Forward P/E (NTM)

ICCCN/A

PTHSN/A

Forward P/S (NTM)

ICCCN/A

PTHS0.83x

Revenue (TTM)

ICCC$31M

PTHS$43M

Revenue Growth (YoY)

ICCC8.5%

PTHSN/A

Forward Rev Growth

ICCC0.0%

PTHS76.2%

Gross Margin (TTM)

ICCC40.3%

PTHS78.6%

Operating Margin (TTM)

ICCC3.9%

PTHS0.0%

EBITDA Margin (TTM)

ICCC20.4%

PTHS-121.6%

Net Margin (TTM)

ICCC2.6%

PTHS-165.2%

FCF Margin (TTM)

ICCC13.7%

PTHS-116.6%

Net Income (TTM)

ICCC$787K

PTHS$-72M

FCF (TTM)

ICCC$4M

PTHS$-50M

EPS (TTM)

ICCC$0.09

PTHS-$20.22

ROE (TTM)

ICCC2.7%

PTHS-7804.0%

ROA (TTM)

ICCC1.8%

PTHS-6701.0%

ROIC (TTM)

ICCC2.1%

PTHS-5896.0%

Cash

ICCC$9M

PTHS$0

Debt

ICCC$8M

PTHS$0

Net Cash/Debt

ICCC$557K

PTHS$0

Current Ratio (TTM)

ICCC4.75x

PTHS2.05x

Quick Ratio (TTM)

ICCC2.65x

PTHS1.10x

Debt/Equity (TTM)

ICCC0.26x

PTHS0.81x

Debt/Assets (TTM)

ICCC0.0%

PTHS0.0%

Interest Coverage (TTM)

ICCCN/A

PTHSN/A

Net Debt/EBITDA (TTM)

ICCC0.00x

PTHS0.00x

Beta

ICCC0.60

PTHS3.13

52W Performance

ICCC48.7%

PTHS-27.4%

YTD Performance

ICCC65.5%

PTHS-30.4%

% from 52W High

ICCC-19.0%

PTHS-45.3%

% from 52W Low

ICCC116.8%

PTHS12.7%

Asset Turnover (TTM)

ICCC0.69x

PTHS0.00x

FCF Yield (TTM)

ICCC4.8%

PTHS-70.8%

Earnings Yield (TTM)

ICCC0.9%

PTHS-100.3%

Dividend Yield (TTM)

ICCCN/A

PTHSN/A

Rule of 40

ICCC22.2

PTHS-116.6

EV/GP/RG

ICCCN/A

PTHS0.02

Ticker research

View ICCC research View PTHS research

Metric	ICCC ImmuCell Corp	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$89M	$71M
Enterprise Value	$88M	$71M
Price	$9.80	$20.50
P/E Ratio	114.37x	N/A
P/S Ratio	2.89x	1.65x
EV/Sales	2.87x	1.65x
EV/EBITDA	14.10x	0.00x
P/B Ratio	2.82x	2.03x
P/FCF Ratio	21.04x	N/A
EV/FCF	20.91x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.83x
Revenue & Growth
Revenue (TTM)	$31M	$43M
Revenue Growth (YoY)	8.5%	N/A
Forward Rev Growth	0.0%	76.2%
Profitability
Gross Margin (TTM)	40.3%	78.6%
Operating Margin (TTM)	3.9%	0.0%
EBITDA Margin (TTM)	20.4%	-121.6%
Net Margin (TTM)	2.6%	-165.2%
FCF Margin (TTM)	13.7%	-116.6%
Net Income (TTM)	$787K	$-72M
FCF (TTM)	$4M	$-50M
EPS (TTM)	$0.09	-$20.22
ROE (TTM)	2.7%	-7804.0%
ROA (TTM)	1.8%	-6701.0%
ROIC (TTM)	2.1%	-5896.0%
Financial Health
Cash	$9M	$0
Debt	$8M	$0
Net Cash/Debt	$557K	$0
Current Ratio (TTM)	4.75x	2.05x
Quick Ratio (TTM)	2.65x	1.10x
Debt/Equity (TTM)	0.26x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.60	3.13
52W Performance	48.7%	-27.4%
YTD Performance	65.5%	-30.4%
% from 52W High	-19.0%	-45.3%
% from 52W Low	116.8%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.69x	0.00x
FCF Yield (TTM)	4.8%	-70.8%
Earnings Yield (TTM)	0.9%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	22.2	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View ICCC research	View PTHS research